Document:

Amendment No. 4 to License Agreement, dated as of February 5, 2009

 EXHIBIT 10.79 
 AMENDMENT 4 TO LICENSE AGREEMENT 
 This Amendment 4 to License Agreement (the “Amendment”)
is made and entered into as of the 5th day of February, 2009 (“Execution Date”), by and between SOLVAY PHARMACEUTICALS, INC., a Georgia corporation having its principal office at 901 Sawyer Road, Marietta, Georgia 30062
(“Solvay”) and JPI COMMERCIAL, LLC, a Delaware limited liability corporation and wholly-owned subsidiary of Jazz Pharmaceuticals, Inc., a Delaware corporation (“Jazz Pharmaceuticals”), having its principal offices at 3180 Porter
Drive, Palo Alto, California 94304 (“JPI”). Solvay and JPI are referred to herein on occasion separately as a “Party” or together as the “Parties”. Capitalized terms used herein shall have their respective meanings set
forth in the License Agreement, unless otherwise defined herein. 
 WHEREAS, Solvay
and JPI are parties to that certain License Agreement (the “Agreement”) dated as of the 31st day of January, 2007, as amended on
March 12, 2008, October 17, 2008 and December 19, 2008; 
 WHEREAS, the Parties wish to amend the Agreement as set forth
below. 
 NOW, THEREFORE, in consideration of the revised milestone payments and elimination of the royalty payable by Jazz as well as the mutual covenants
and promises set forth in this Amendment, the Parties agree as follows: 
 1. Amendment of Definitions. 
 (a) Section 1.11 of the Agreement is amended and replaced in its entirety with the following: 
 “1-11 “Milestones” means the events identified in Sections 3.1 (b) through (k).” 
 (b) Section 1.12 of the Agreement is amended and replaced in its entirety with the following: 
 “1.12 “Milestone Payments” means the payments to be made by Jazz Pharmaceuticals and/or JPI to Solvay pursuant to Sections 3.1
(b) through (k).” 
 2. Amendment of Section 3.1. Section 3.1 of the Agreement is amended and replaced in its entirety with the
following: 
 “3.1 Upfront Payment and Milestone Payments. As consideration for the license granted by Solvay to Jazz
Pharmaceuticals hereunder, Jazz Pharmaceuticals and/or JPI will make the following upfront and milestone payments to Solvay: 
 (a) Two
million ($2,000,000.00) dollars to be paid as a non-refundable payment at the Time of Closing (the “Upfront Payment”); 

 (b) Two million ($2,000,000.00) dollars within fifteen (15) days of the First Commercial Sale of
LUVOX-IR, supplied by or on behalf of Solvay, by Jazz Pharmaceuticals; 
 (c) Ten million dollars ($10,000,000.00) within thirty
(30) days after receipt of FDA approval of the first indication for the LUVOX CR NDA; 
 (d) Ten million dollars ($10,000,000.00) within
thirty-nine (39) days after receipt of FDA approval of the first indication for the LUVOX CR NDA; 
 (e) Three million five hundred
thousand dollars ($3,500,000.00) on October 20, 2008; 
 (f) Three million five hundred thousand dollars ($3,500,000.00) on
November 15, 2008; 
 (g) Six million dollars ($6,000,000.00) payable in 2009 in four (4) quarterly installments as follows: one
million dollars ($1,000,000.00) on or before March 15, 2009; one million dollars ($1,000,000.00) on or before June 15, 2009; two million dollars ($2,000,000.00) on or before September 15, 2009; and two million dollars ($2,000,000.00)
on or before December 15, 2009. 
 (h) Four million dollars ($4,000,000.00) payable in 2010 in four (4) equal quarterly installments
of one million dollars ($1,000,000.00), said installments to be paid on or before March 15, 2010, June 15, 2010, September 15, 2010 and December 15, 2010; 
 (i) Four million five hundred thousand dollars ($4,500,000.00) payable in 2011 in four (4) equal quarterly installments of one million one hundred
twenty-five thousand dollars ($1,125,000,00), said installments to be paid on or before March 15, 2011, June 15, 2011, September 15, 2011 and December 15, 2011; 
 j) Five million dollars ($5,000,000.00) payable in 2012 in four (4) equal quarterly installments of one million two hundred fifty thousand dollars
($1,250,000.00), said installments to be paid on or before March 15, 2012, June 15, 2012, September 15, 2012 and December 15, 2012; and 
 (k) Five million dollars ($5,000,000.00) payable on January 15, 2015 if (i) Net Sales of Luvox-CR have reached a cumulative amount of one hundred million dollars ($100,000,000.00) on or before
December 31, 2014 and (ii) no AB-rated generic version of Luvox-CR is being sold in the United States of America on or before December 31, 2014. 
 Notwithstanding the terms of Section 3.1(j) in the event Jazz Pharmaceuticals and/or JPI makes each and every installment payment pursuant to Section 3.1(g), Section 3.1(h), Section 3.1(i) and the first three
(3) installments of Section 3.1(j) on or before the respective dates set forth therein, Jazz Pharmaceuticals and/or JPI shall be entitled to reduce the amount of the installment payment due on or before December 15, 2012 to seven
hundred fifty thousand dollars ($750,000.00).” 
 3. Amendment of Section 3.3. Section 3.3 of the Agreement is amended and replaced in
its entirety with the following: 
 “33 Royalty Payments. Intentionally Deleted.” 

 4. Amendment of Section 3.5. Section 3.5 of the Agreement is amended and replaced with the following:

 “3.5 Reports. Within forty-five (45) days after the end of each calendar quarter during the term of this Agreement, Jazz
Pharmaceuticals and/or JPI shall provide Solvay with a written report of Net Sales of LUVOX CR during such quarter. Interest, at a rate of twelve percent (12%) per annum, or at the highest legal rate if less than 12%, shall be payable for any
late payments.” 
 5. Amendment of Section 11.2. Section 11.2 of the Agreement is amended and replaced in its entirety with the
following: 
 “11.2 Termination for Breach. This Agreement may be terminated by either Party in the event the other Party
breaches its obligation(s) under this Agreement and does not cure the same within sixty (60) days following written notice of such breach; provided, however, that if the breach is of a nature that it cannot be cured within sixty (60) days,
then the time to cure shall be extended until such breach can reasonably be cured. Notwithstanding the foregoing and anything to the contrary, Solvay may terminate this Agreement immediately if any Milestone Payment required pursuant to Sections
3.1(g), (h), (i), (j) and/or (k) is not paid within fifteen (15) days after such Milestone Payment became due and payable.” 
 6.
Release of Claims. As of the Execution Date, Jazz Pharmaceuticals and/or JPI do hereby forever release and discharge Solvay, its directors, officers, agents, attorneys, affiliates, partners, subsidiaries, successors, assigns, and past and
present employees (the “Released Parties”), from any and all causes of action, actions, judgments, liens, damages, losses, claims, liabilities and demands whatsoever, whether known or unknown and whether based upon legal or equitable
theories, which Jazz Pharmaceuticals and/or JPI ever had, now has or may have against the Released Parties by reason of any matter up to and including the Execution Date. The release contained herein does not apply to rights or claims arising after
the Execution Date. 
 7. No Other Changes. Except as set forth above, the Agreement remains in full force and effect. 

 IN WITNESS WHEREOF, the Parties have caused this Amendment to the License Agreement to be executed by their duly
authorized representatives as of the Execution Date. 
  

									
	JPI COMMERCIAL, LLC	 		 	SOLVAY PHARMACEUTICALS, INC.
					
	By:	 	/s/ Carol Gamble	 		 	By:	 	/s/ Murray Kay
	Print Name:	 	Carol Gamble	 		 	Print Name:	 	Murray Kay
	Title:	 	Sr. Vice President & General Counsel	 		 	Title:	 	Vice President, Finance
	Date:	 	2/5/09	 		 	Date:	 	2/5/09Directors Deferred Compensation Plan, as amended

 EXHIBIT 10.80 
 JAZZ PHARMACEUTICALS, INC. 
 DIRECTORS
DEFERRED COMPENSATION PLAN 
 APPROVED BY THE
BOARD: MAY 1, 2007 
 AMENDED DECEMBER 16, 2008 
 ARTICLE I 
 DEFINITIONS

 1.1 “Board” shall mean the Board of Directors of the Company. 
 1.2 “Change in Control” means any of the following: (a) the date that any one person or persons acting as a group
acquires ownership of Company stock constituting more than fifty percent (50%) of the total fair market value or total voting power of the stock of the Company; (b) the date that any one person or persons acting as a group acquires (or has
acquired during the 12-month period ending on the date of the most recent acquisition by such person or persons) ownership of the stock of the Company possessing fifty percent (50%) or more of the total voting power of the stock of the Company;
(c) the date that a majority of members of the Board is replaced during any 12-month period by directors whose appointment or election is not endorsed by a majority of the members of the Board before the date of the appointment or election; or
(d) the date that any one person or persons acting as a group acquires assets (or has acquired during the 12-month period ending on the date of the most recent acquisition by such person or persons) from the Company that have a total gross fair
market value equal to or more than eighty percent (80%) of the total gross fair market value of all of the assets of the Company immediately prior to such acquisition or acquisitions. The determination of whether an event constitutes a Change
of Control for purposes of this Plan shall be made in accordance with its definition under Section 409A of the Code and the regulations and other guidance thereunder, and shall not involve the exercise of any discretionary authority by the
Board. 
 1.3 “Code” shall mean the Internal Revenue Code of 1986, as amended. 
 1.4 “Common Stock” shall mean the common stock of the Company. 
 1.5 “Company” means Jazz Pharmaceuticals, Inc., a Delaware corporation. 
 1.6 “Director” shall mean a member of the Board who is not an employee of the Company or any of its subsidiaries.

 1.7 “Exchange Act” means the Securities Exchange Act of 1934, as amended. 
 1.8 “Fees” shall mean amounts earned for serving as a member of the Board, including any committees of the Board.

 1.9 “He”, “Him”, or “His” shall apply equally to male and
female members of the Board. 
  

 1. 

 1.10 “Market Value Per Share” shall mean, for any given day, the price per
share equal to (i) the last sale price of the Common Stock on the such day on the principal stock exchange on which the Common Stock may at the time be listed or, (ii) if there shall have been no sales on such exchange on such day, the
average of the closing bid and asked prices of the Common Stock on such exchange on such day or, (iii) if there is no such bid and asked price on such day, the average of the closing bid and asked prices of the Common Stock on the next
preceding date when such bid and asked price occurred or, (iv) if the Common Stock shall not be so listed, the closing sales price of the Common Stock as reported by NASDAQ on such day in the over-the-counter market. 
 1.11 “Plan” shall mean the Jazz Pharmaceuticals, Inc. Directors Deferred Compensation Plan for Directors, as it may be
amended from time to time. 
 1.12 “Stock Account” shall mean the account created by the Company pursuant to
Article III of this Plan in accordance with an election by a Director to receive stock compensation under Article II hereof. 
 1.13
“Year” shall mean a calendar year. 
 ARTICLE II 
 ELECTION TO DEFER 
 2.1 This Plan was effective May 31, 2007.

 2.2 A Director may elect, on or before December 15 of any Year, to defer payment of all or a specified part of all Fees to be
earned during the Year following the Year in which such election occurs and succeeding Years (until the Director ceases to be a Director or changes his election pursuant to Section 2.4 herein); provided, however, that with respect to the
first Year in which a Director becomes eligible to participate in the Plan, the Director may make an initial election within thirty (30) days after the date the Director becomes so eligible to defer payment of all or a specified part of such
Fees earned following the date on which such initial election is made during the remainder of such Year and for any succeeding Years. 
 2.3 The election to participate in the Plan and manner of payment shall be designated by submitting a letter in the form attached hereto as Appendix A to the Secretary of the Company. 
 2.4 The election shall continue from Year to Year and become irrevocable on December 15 of each Year, unless the Director changes or
terminates it by written request delivered to the Secretary of the Company prior to December 15 of the Year preceding the commencement of the Year for which the changes or termination is first effective. 
  

 2. 

 ARTICLE III 
 DEFERRED COMPENSATION ACCOUNTS 
 3.1 The Company shall maintain separate memorandum accounts
for the Fees deferred by each Director. 
 3.2 The Company shall credit, on the date Fees become payable, the Stock Account of each
Director with a number of shares of Common Stock which is equal to the deferred portion of any Fee due the Director as to which an election to defer Fees into the Stock Account has been made, divided by the Market Value Per Share determined as of
the date such Fees would otherwise have been paid. 
 3.3 The Company shall credit the Stock Account of each Director who has elected
to receive deferred compensation in the form of Common Stock with the number of shares of Common Stock equal to any cash dividends (or the fair market value of dividends paid in property other than dividends payable in Common Stock) payable on the
number of shares of Common Stock represented in each Director’s Stock Account, divided by the Market Value Per Share on the applicable dividend payment date. Dividends payable in Common Stock will be credited to each Director’s Stock
Account in the form of the right to receive Common Stock. If adjustments are made to the outstanding shares Common Stock as a result of split-ups, recapitalizations, mergers, consolidations and the like, an appropriate adjustment also will be made
in the number of shares of Common Stock credited to the Director’s Stock Account. 
 3.4 Common Stock shall be computed to three
decimal places. 
 3.5 The right to receive Common Stock at a later date shall not entitle any person to rights of a stockholder with
respect to such Common Stock unless and until shares of Common Stock have been issued to such person pursuant to Article IV hereof. 
 3.6
The Stock Account of a Director shall only be a bookkeeping account, and the Company shall not be required to acquire, reserve, segregate, or otherwise set aside shares of its Common Stock for the payment of its obligations under the Plan. The
Company shall make available as and when required a sufficient number of shares of its Common Stock to meet the needs of the Plan. 
 3.7
Nothing contained herein shall be deemed to create a trust of any kind or any fiduciary relationship. To the extent that any person acquires a right to receive payments from the Company under the Plan, such right shall be no greater than the
right of any unsecured general creditor of the Company. 
 ARTICLE IV 
 PAYMENT OF DEFERRED COMPENSATION 
 4.1 Subject to the other provisions of
this Article IV, amounts credited to a Director’s Stock Account shall be distributed as the Director’s election (made pursuant to Paragraph 2.2 of Article II hereof) shall provide. Distributions in respect of the Director’s Stock
Account shall be paid in Common Stock, and any such distributions shall begin on the tenth (10th) business day following the day on which a Director separates from service with the Board, or as soon thereafter as practical once the former
Director has provided the necessary information for electronic deposit of the shares. Shares of Common Stock available for distribution shall be funded with shares reserved under the Company’s 2007 Non-Employee Directors Stock Option Plan.

  

 3. 

 4.2 Each Director shall have the right to designate one or more beneficiaries to succeed to his
right to receive payments hereunder in the event of his death. Each designated beneficiary shall receive payments in the same manner as the Director if he had lived. If no beneficiary is designated, the Director’s estate shall receive payments
in the same manner as the Director if he had lived. No beneficiary designation shall be valid unless it is in writing, signed by the Director and filed with the Secretary of the Company. 
 4.3 In the event of a Change in Control, all amounts credited to each Director’s Stock Account shall be distributed on the tenth
(10th) business day after the occurrence of such Change in Control. 
 ARTICLE V 
 ADMINISTRATION 
 5.1 The
Company shall administer the Plan at its expense. All decisions made by the Company with respect to issues hereunder shall be final and binding on all parties. 
 5.2 Except to the extent required by law, the right of any Director or any beneficiary to any benefit or to any payment hereunder shall not be subject in any manner to attachment or other legal process for the
debts of such Director or beneficiary; and any such benefit or payment shall not be subject to alienation, sale, transfer, assignment or encumbrance. 
 ARTICLE VI 
 AMENDMENT OF PLAN; GOVERNING LAW; SECTION 409A. 
 6.1 The Plan may be amended, suspended or terminated in whole or in part from time to time by the Board except that no amendment, suspension, or
termination shall apply to the payment of any amounts previously credited to a Director’s Stock Account. 
 6.2 The Plan shall be
governed by and construed and enforced in accordance with the laws of the State of Delaware, without regard to principles of conflict of law. 
 6.3 Notwithstanding any other provision of the Plan, this Plan is intended to comply with Section 409A and shall at all times be interpreted in accordance with such intent such that amounts credited to Directors’ accounts
shall not be taxable to Directors until such amounts are paid to Directors in accordance with the terms of the Plan. In furtherance thereof, no payments may be accelerated under the Plan other than to the extent permitted under Section 409A of
the Code (“Section 409A”). To the extent that any provision of the Plan violates Section 409A such that amounts would be taxable to a Director prior to payment or would otherwise subject a Director to a penalty tax under
Section 409A, such provision shall be automatically reformed or stricken to preserve the intent hereof. To the extent that the Company determines that Directors may be given greater flexibility to modify or revoke deferral elections under the
Plan in a manner consistent with Section 409A (based on future guidance promulgated by the Internal Revenue Service and the Treasury Department from time to time), the Company may (but shall not be obligated to) amend the Plan to provide for
such greater flexibility. 
  

 4. 

 APPENDIX A – DEFFERAL ELECTION FORM 
 [Date] 
 Jazz Pharmaceuticals, Inc. 
 3180 Porter Drive 
 Palo Alto, CA 94304 
 Ladies and Gentlemen: 
 Pursuant to the Jazz
Pharmaceuticals, Inc. Directors Deferred Compensation Plan, adopted on May 1, 2007 (the “Plan”), I hereby elect to defer receipt of all or a portion of my Director’s fees to which I may become entitled to receive in
respect of 20__ and succeeding Years (unless and until I change my election for fees receivable in succeeding years pursuant to the terms of the Plan) in accordance with the percentages indicated below. 
 Initial Deferral Election. I hereby elect to have my director’s fees (and committee fees, if any) credited as follows (fill in
appropriate percentages for options a and b below): 
 (a) _____% of the aggregate fees shall be credited to my Stock
Account as provided for in the Plan; or 
 (b) _____% of the aggregate fees shall not be deferred, but shall be paid to
me directly and promptly as they accrue. 
 Timing of Distributions. I understand that my Stock Account shall each become
payable on the earlier to occur of the tenth (10th) business day following (i) the date of my separation from service with the Board and (ii) a Change in Control (as such term is defined in the Plan), or as soon thereafter as
practical once I have provided the necessary electronic delivery information. 
 Manner of Distributions. Further, I elect to
receive the payments pursuant to the Plan (check one desired method below): 
 (a)    If a
distribution results due to my separation from service with the Board: 
 ____ in one lump sum; 
 ____ in (insert number) equal annual installments. 
 (b)    If a distribution results due to a Change in Control: 
 in one lump sum; 
 in (insert number) equal annual installments. 
  

	
	Very truly yours,
	
	  
	[Name]

  

 5. 

 DESIGNATION OF BENEFICIARY 
 JAZZ PHARMACEUTICALS, INC. 
 DIRECTORS DEFERRED COMPENSATION PLAN 
 In
the event of my death prior to receipt of all or any amount of the balance of my Stock Account so accumulated, I designate the following one or more individual(s): 
  

			
		
	 	  	
		
	 	  	
		
	 	  	

 as my beneficiary or beneficiaries to receive the funds so accumulated, but unpaid. 
 Signed this                  day of
                        , 20        . 
  

	
	
	  
	Signature

  

	
	
	  
	Print Name

 Witnessed this
                 day of
                        , 20        . 
  

	
	
	  
	Print Name of Witness

  

 6.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00156-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00156-of-00352.parquet"}]]